Study of the diagnostic difference between the clinical diagnostic criteria and results of immunohistochemical staining of multiple primary lung cancers

AIM: When multiple synchronous or metachronous lung cancer lesions are identified, discrimination of multicentric lung cancers from intrapulmonary metastases by clinical findings is often difficult. When tissue types have the same pathological features, such as combinations of squamous cell carcinoma (SCC), adenocarcinoma (AD) or bronchiolo-alveolar cell carcinoma (BAC), it is especially difficult to distinguish a 2(nd) primary lung cancer from a metastatic lesion. A new strategy for accurate diagnosis of multiple synchronous or metachronous lung cancer is needed because of the difficulty of histological discrimination. METHODS: Of 363 patients with primary lung cancer for which surgeries were conducted at our hospital, 7 cases were diagnosed as synchronous multiple lung cancer (BAC-BAC in 4 cases and SCC-BAC in 3 cases) and 8 cases (BAC-BAC in 2 cases, AD-BAC in 1 case, AD-AD in 1 case, SCC-AD in 1 case and SCC-SCC in 3 cases) were diagnosed as metachronous multiple lung cancer according to the clinical diagnostic criteria. This study focused on 8 cases with the combinations AD-AD, AD-BAC, or BAC-BAC. For immunohistochemical staining, we used the antibodies to 6 antigens as follows: CK-19, p53, CEA, Hup-1, PE-10, and Ki-67. RESULTS: Of 4 cases diagnosed as synchronous lung cancer according to the clinical diagnostic criteria, differing immunohistochemical stained images of the lesions were observed in 3 cases, while in the 4th case almost identical immunohistochemical stained images were obtained, which indicated the 2 lesions were the primary and metastatic focuses. Of 4 cases diagnosed as metachronous lung cancer according to the clinical diagnostic criteria, almost identical stained images were seen in 3 cases, which indicated the 2 lesions were the primary and metastatic focuses. CONCLUSION: In general, Type A and Type B in Noguchi's BAC classification, tended to be multiple synchronous or metachronous lung cancer lesions, while AD and Type C in Noguchi's BAC classification tended to be the metastatic focus. For the focuses with tissue type of BAC-BAC, the staining using CK-19, PE-10, and Ki-67 was useful in distinguishing multiple primary lung cancer from pulmonary metastasis in cases with a combination of AD and BAC.     

Lung cancer in patients with head and neck cancer. Incidence and long-term survival

Of the 3,907 cases of primary head and neck or lung cancer diagnosed between 1961 and 1984, 94 patients were identified with a history of cancer at both sites. The total incidence of lung cancer in our head and neck cancer patients was 5.4 percent. Of the 94 patients, 73 had both cancers diagnosed at our institution. These 73 patients were further analyzed. Squamous cell carcinoma accounted for 63 percent of the lung cancers. Twenty of the lung cancers were synchronous and 47 were metachronous after head and neck cancer. Of the synchronous lung cancers, 50 percent were postoperative stage I, whereas only 11 percent of the metachronous cancers were postoperative stage I. The lung cancer survival rate was significantly better for the synchronous cancer group at 5 years (34 percent) than for the metachronous cancer group (5 percent). The better survival rate was evidently due to the greater proportion of early-stage lung lesions. The relatively large number of advanced-stage lung lesions in the metachronous cancer group suggests that aggressive screening of head and neck cancer patients for lung cancer may detect more metachronous lung cancers at an earlier stage and thus improve the survival rate of these patients.     

Multiple primary lung carcinomas: prognosis and treatment

From 1955 to 1990, 111 patients have been treated for multiple primary lung carcinomas. Criteria for diagnosis were: (1) different histology (n = 44); or (2) same histology, but disease-free interval at least 2 years (n = 39), origin from carcinoma in situ (n = 19), or metachronous disease in different lobe (n = 9) with no cancer in common lymphatics or extrapulmonary metastasis at the time of diagnosis. The second cancer was synchronous in 33 patients (30%) and metachronous in 78 (70%). Metachronous disease developed at a median interval of 48 months. Five-year survival for patients with metachronous and synchronous disease from the time of initial diagnosis of cancer was 70% and 44%, and 10-year survival was 42% and 23%, respectively. Survival after the development of a metachronous lesion was 23% at 5 years. Survival from the time of initial diagnosis was significantly better for metachronous versus synchronous, late (24 month disease-free interval) versus early metachronous disease, and adenocarcinoma versus epidermoid carcinoma. The first cancer was completely resected in 103 patients (93%), but complete resection of a metachronous tumor was possible in only 54 patients (69%). Complete resection of second primary cancers resulted in significantly (p less than 0.0001) prolonged 5-year survival compared with incomplete resection (38% versus 9%). Excluding patients requiring pneumonectomy, initial resection limited subsequent resection in only 7 patients (9%) with metachronous disease. We conclude that patients surviving treatment of primary lung cancers require lifelong screening for multiple primary lung carcinoma, and complete resection is recommended whenever possible.     

Synchronous or metachronous double cancers of the pancreas and other organs: Report on 12 cases

Pancreatic carcinoma carries a poor prognosis, especially invasive ductal carcinoma of the pancreas. This retrospective study describes the results of the treatment and prognosis for double cancers in which cancer of the pancreas was associated with malignancies in other organs in 12 patients who were diagnosed and treated at Kurume University Hospital. The patients included 4 women and 8 men, with an average age of 67 years. Of the 12 tumors, 7 were metachronous pancreatic cancers which occurred after resections of other organ malignancies. Five patients had synchronous double cancers, one of whom was diagnosed to have gastric cancer on admission. Two other patients of this group were diagnosed to have lung cancer, while the remaining 2 patients suffered from colon cancer. By the time pancreatic cancer was diagnosed, gastrectomies had been performed in 7 patients for either gastric cancer or ulcers. In addition, one patient underwent a hysterectomy for uterine carcinoma and another received a low anterior resection for rectal carcinoma. Four of 5 patients in the synchronous group had nonresectable tumors and a palliative bypass operation was performed in 2 of these patients. Six patients who had metachronous double cancers died because of pancreatic cancer recurrence or metastases. We conclude that the prognosis of double cancers, where cancer of the pancreas is associated with other organ malignancies, primarily depends on the prognosis of the pancreatic carcinoma, and the present study suggests the necessity of long-term follow-up examinations for gastrectomy patients in order to make an early diagnosis of pancreatic cancer. Received: September 24, 1999 / Accepted: March 24, 2000     

The management of second primary lung cancers. A single centre experience in 15 years.

OBJECTIVE: In patients treated for an initial lung cancer, the cumulative risk of developing a second primary lung cancer is a recognised occurrence. This study reviews our experience in the clinical assessment and surgical management of second primary lung cancer (SPLC). METHODS: Between 1985-1999 a series of 892 patients with primary carcinoma of lung underwent surgical resection with curative intent in our institution. Using criteria set out by Martini and Melamed (J Thorac Cardiovasc Surg 70 (1975) 606) we were able to identify 51 patients who had developed a SPLC identified as the first site of re-occurrence. RESULTS: Forty-one patients developed a metachronous SPLC within a mean of 46+/-14 months of the first operation while ten patients had synchronous double lung cancer (six unilateral, four bilateral). The cumulative probability of cancer free interval for metachronous cancers was 39% at 3 years, 15% at 5 years and 2% at 10 years. There were three postoperative deaths among the metachronous cancers (7.5%) and there were no operative deaths among patients with synchronous cancers. The overall actuarial 5-year survival for all patients with SPLC was 38% with a median survival of 40 months (range 1-142 months). The actuarial 5-year survival for metachronous SPLC was 44%, median survival of 49 months (range 1-142 months), while the actuarial 5-years survival for synchronous SLPC was 10% with a median survival of 31 months (range 4-78 months). CONCLUSION: Aggressive assessment and surgical intervention is safe, effective and warranted in patients with a second lung primary cancer if they satisfy the usual criteria of operability after full assessment. This is true for patients with metachronous cancers, while patients with synchronous cancers tend to have worse prognosis. A long term follow-up policy after the initial resection of the primary lung cancer is recommended at intervals of 6 months for at least 3-5 years and then annually to enable the early detection of the second cancer.     

双原发肺癌外科治疗的疗效分析

目的 探讨双原发肺癌的外科治疗结局和长期生存率.方法 对1999年1月至2009年6月收治的98例双原发肺癌患者的临床资料进行回顾性分析.同时双原发肺癌患者共72例,其中男性54例,女性18例;发病中位年龄66岁.异时双原发肺癌患者26例,其中男性20例,女性6例;第一原发癌发病中位年龄59.5岁,第二原发癌发病中位年龄66岁.同时双原发肺癌患者72例,144个肿瘤病灶,手术方式包括肺叶切除9例,双肺叶切除14例,全肺切除6例,肺叶切除并楔形切除33例,双楔形切除9例,双肺叶切除并楔形切除1例;异时双原发肺癌患者26例,52个肿瘤病灶,手术方式包括肺叶切除31次,双肺叶切除1次,楔形切除10次,全肺切除8次.结果 全组患者术后30 d病死率为0,术后并发症发生率为13.3%.全组患者从术后开始随访至2009年12月,随访率＞90%.全组患者从发现第一原发癌开始计算,其5年生存率为66.4%.异时第一原发肺癌和同时双原发肺癌的5年生存率差异有统计学意义(96.2%比43.0%,P=0.000).异时第二原发肺癌和同时双原发肺癌的5年生存率差异无统计学意义(45.9%比43.0%,P=0.634).结论 外科手术治疗双原发肺癌是合理的,能使患者获得较高的长期生存预期.     

双原发肺癌外科治疗的疗效分析

目的 探讨双原发肺癌的外科治疗结局和长期生存率.方法 对1999年1月至2009年6月收治的98例双原发肺癌患者的临床资料进行回顾性分析.同时双原发肺癌患者共72例,其中男性54例,女性18例;发病中位年龄66岁.异时双原发肺癌患者26例,其中男性20例,女性6例;第一原发癌发病中位年龄59.5岁,第二原发癌发病中位年龄66岁.同时双原发肺癌患者72例,144个肿瘤病灶,手术方式包括肺叶切除9例,双肺叶切除14例,全肺切除6例,肺叶切除并楔形切除33例,双楔形切除9例,双肺叶切除并楔形切除1例;异时双原发肺癌患者26例,52个肿瘤病灶,手术方式包括肺叶切除31次,双肺叶切除1次,楔形切除10次,全肺切除8次.结果 全组患者术后30 d病死率为0,术后并发症发生率为13.3%.全组患者从术后开始随访至2009年12月,随访率＞90%.全组患者从发现第一原发癌开始计算,其5年生存率为66.4%.异时第一原发肺癌和同时双原发肺癌的5年生存率差异有统计学意义(96.2%比43.0%,P=0.000).异时第二原发肺癌和同时双原发肺癌的5年生存率差异无统计学意义(45.9%比43.0%,P=0.634).结论 外科手术治疗双原发肺癌是合理的,能使患者获得较高的长期生存预期.

Abstract：

Objective To verify the outcome and long-term survival of surgical management for double primary lung cancers. Methods The clinical data of 98 patients with double primary lung cancers admitted between January 1999 and June 2009 was analyzed retrospectively. There were 72 cases of synchronous double primary lung cancers, including 54 males and 18 females with median age of onset of 66 years (37 to 79 years). Thoracic surgical procedures for 144 tumor lesions included lobectomy for 9 cases, bilobectomy for 14 cases, pneumonectomy for 6 cases, lobectomy plus wedge resection for 33 cases, double wedge resection for 9 cases, and bilobectomy plus wedge resection for 1 case. There were 26 cases of metachronous double primary lung cancers, including 20 males and 6 females. The median age for the first primary cancer was 59. 5 years (38 to 73 years) , for second primary cancer was 66 years (47 to 77 years). Thoracic surgical procedures for 52 tumor lesions included lobectomy for 31 cases, bilobectomy for 1 cases, wedge resection for 10 cases, and pneumonectomy for 8 cases. Results The overall 30-day mortality was 0.Postoperative complications rate was 13. 3% . All patients were followed up after the operation. Until December 2009, follow-up rate was over 90%. Five-year survival for all the patients from the time of initial diagnosis of cancer was 66. 4%. Five-year survival for patients with metachronous and synchronous disease from the time of initial diagnosis of cancer was 96. 2% and 43. 0% ( P =0. 000) , respectively. Survival at 5 years for the second cancer of metachronous disease and synchronous disease was 45. 9% and 43. 0% (P =0. 634) ,respectively. Conclusion Surgical treatment for double primary lung cancer is reasonable, and the patients can make long-term survival.     

双原发肺癌外科治疗的疗效分析

目的 探讨双原发肺癌的外科治疗结局和长期生存率.方法 对1999年1月至2009年6月收治的98例双原发肺癌患者的临床资料进行回顾性分析.同时双原发肺癌患者共72例,其中男性54例,女性18例;发病中位年龄66岁.异时双原发肺癌患者26例,其中男性20例,女性6例;第一原发癌发病中位年龄59.5岁,第二原发癌发病中位年龄66岁.同时双原发肺癌患者72例,144个肿瘤病灶,手术方式包括肺叶切除9例,双肺叶切除14例,全肺切除6例,肺叶切除并楔形切除33例,双楔形切除9例,双肺叶切除并楔形切除1例;异时双原发肺癌患者26例,52个肿瘤病灶,手术方式包括肺叶切除31次,双肺叶切除1次,楔形切除10次,全肺切除8次.结果 全组患者术后30 d病死率为0,术后并发症发生率为13.3%.全组患者从术后开始随访至2009年12月,随访率＞90%.全组患者从发现第一原发癌开始计算,其5年生存率为66.4%.异时第一原发肺癌和同时双原发肺癌的5年生存率差异有统计学意义(96.2%比43.0%,P=0.000).异时第二原发肺癌和同时双原发肺癌的5年生存率差异无统计学意义(45.9%比43.0%,P=0.634).结论 外科手术治疗双原发肺癌是合理的,能使患者获得较高的长期生存预期.     

双原发肺癌外科治疗的疗效分析

目的 探讨双原发肺癌的外科治疗结局和长期生存率.方法 对1999年1月至2009年6月收治的98例双原发肺癌患者的临床资料进行回顾性分析.同时双原发肺癌患者共72例,其中男性54例,女性18例;发病中位年龄66岁.异时双原发肺癌患者26例,其中男性20例,女性6例;第一原发癌发病中位年龄59.5岁,第二原发癌发病中位年龄66岁.同时双原发肺癌患者72例,144个肿瘤病灶,手术方式包括肺叶切除9例,双肺叶切除14例,全肺切除6例,肺叶切除并楔形切除33例,双楔形切除9例,双肺叶切除并楔形切除1例;异时双原发肺癌患者26例,52个肿瘤病灶,手术方式包括肺叶切除31次,双肺叶切除1次,楔形切除10次,全肺切除8次.结果 全组患者术后30 d病死率为0,术后并发症发生率为13.3%.全组患者从术后开始随访至2009年12月,随访率＞90%.全组患者从发现第一原发癌开始计算,其5年生存率为66.4%.异时第一原发肺癌和同时双原发肺癌的5年生存率差异有统计学意义(96.2%比43.0%,P=0.000).异时第二原发肺癌和同时双原发肺癌的5年生存率差异无统计学意义(45.9%比43.0%,P=0.634).结论 外科手术治疗双原发肺癌是合理的,能使患者获得较高的长期生存预期.     

Multiple primary cancers in surgically resected lung cancer patients

Among 337 cases of surgically resected lung cancer from April 1977 to March 1984, there were 24 cases (7.12%) of multiple primary cancers including 22 cases of double cancer and one case each of triple and quadruple cancer. They consisted of 17 males and 7 females and the patient age at the time of the lung resection ranged from 32 to 81 years old (average: 67.4). In double cancer cases, the most common site of the other primary cancer was the lung (9 cases), followed by the stomach (5 cases), the colon (4 cases), the pancreas (2 cases), and there was one case each of the salivary gland and the skin. The cases of triple and quadruple cancer involved multiple primary lung cancer associated with mammary and esophageal cancer, respectively. There were 14 synchronous and 8 metachronous cases. The histology of lung cancer in 13 cases of double cancer was adenocarcinoma in 6, squamous cell carcinoma in 2, large cell carcinoma in 3, small cell carcinoma in 1, and adenosquamous cell carcinoma in 1. The histology of 11 cases of double or triple primary lung cancers was squamous cell carcinoma in 17, adenocarcinoma in 5, and large cell carcinoma in 1. In 24 cases 19 lobectomies, 4 pneumonectomies and one partial resection of the lung was performed for the first primary lung cancer. All cancer lesions of other organs apart from the lung were also surgically resected.(ABSTRACT TRUNCATED AT 250 WORDS)     

胃癌合并其他器官原发癌103例分析

目的探讨胃癌合并其他器官恶性肿瘤的发生率、临床病理特征及其诊治和预后情况。方法对我院1983年1月至2010年12月期间治疗的103例胃癌合并其他器官原发癌患者的临床病理资料进行回顾性分析。结果本组103例患者占同期收治胃癌患者的2.26%(103/4 552)。确诊胃癌的年龄为(63.98±11.93)岁(30～84岁)。同时多原发癌29例;异时多原发癌74例,其中胃癌确诊前异时多原发癌46例,胃癌确诊后异时多原发癌28例。共发生胃癌以外恶性肿瘤113个,以结直肠癌最多,占27.43%(31/113),肺癌其次,占15.04%(17/113)。异时癌的发生时间距胃癌确诊前或后(87.95±92.98)个月(7～506个月),65.49%(74/113)合并的原发癌距胃癌确诊的间隔时间在5年内。全组患者总的5年累积生存率为48.43%,其中同时多原发癌患者为36.40%,胃癌确诊前发生多原发癌者为42.31%,胃癌确诊后发生多原发癌者为69.52%,胃癌确诊后发生者的预后明显好于胃癌确诊前发生者和同时发生者(P<0.023,P<0.009)。在死亡原因明确的33例患者中有20例因胃癌死亡。结论胃癌治疗时需注意同时并发其他器官原发癌的可能,对于这类患者胃癌仍然可能是影响其预后的主要原因。     

DNA ploidy patterns of tumors diagnosed as metachronous or recurrent lung cancers

The relationship between the first tumor and the second tumor resected in 8 patients with non-small cell lung cancer was analyzed using deoxyribonucleic acid (DNA) flow cytometry. Of the 8 patients, 6 were clinically diagnosed as having metachronous lung cancers and 2, local recurrent tumors. The mean interval between operations in patients with metachronous lung cancers was 62 months (range, 15 to 128 months). Both tumors showed the same histology in 4 patients and a different histology in 2. In the 2 patients with local recurrent tumors, the interval between operations was 9 months and 39 months. In the analysis of DNA flow cytometry of the first and second tumors in the same patient, the tumors were defined as independent of each other when one tumor showed diploidy and the other, aneuploidy, or when each DNA index of abnormal clones between two aneuploid tumors was different. When both tumors showed diploidy or when at least one DNA index of abnormal clones between two aneuploid tumors was identical, the tumors were defined to be related to each other. According to these criteria, in 5 (83%) of the 6 patients clinically diagnosed as having metachronous lung cancers, the second tumor was classified as independent of the first tumor. On the other hand, in the 2 patients clinically diagnosed as having recurrent tumors, the second tumor was judged to be related to the first tumor. These data suggest that DNA flow cytometric analysis of tumors may be of value in the diagnosis of metachronous lung cancers.     

Double resection for patients with pancreatic cancer and a second primary renal cell cancer

BACKGROUND: Reports of synchronous or metachronous double kidney-pancreas cancers are very rare. METHODS: We present 2 patients with renal cell carcinoma and synchronous (1 patient) or metachronous (1 patient) primary pancreatic ductal adenocarcinoma. The patients underwent resection for both cancer types with a worthwhile outcome. RESULTS: The appearance of different primaries in an individual may indicate a genetic predisposition to different neoplasms. The study of double primary cancers is important because it might provide understanding of a shared genetic basis of different solid tumors. CONCLUSIONS: The association between these two cancers demands more detailed epidemiological and molecular investigation. From a clinical viewpoint a resectional policy is recommended.     

Treatment for bilateral multiple lung cancers

During a 27-year period 1,839 patients with lung cancer were treated at Kanazawa University Hospital. Of these 1,839 patients, 25 (1.3%) were classified as bilateral multiple lung cancers by Martini's criteria. They consisted of 14 synchronous carcinomas and 11 metachronous carcinomas. For the patients with synchronous carcinomas, 5 underwent bilateral operation, and 5 underwent ipsilateral operation and contralateral combination therapy (Nd:YAG, irradiation or chemotherapy). Four did not undergo operation. While for the patients with metachronous carcinomas, 9 underwent operation for bilateral lesions, 2 were treated by radiotherapy for the second primary lung cancer. When a pulmonary resection for bilateral multiple lung cancers is required, radicality and the need to preserve residual respiratory function and cardiac function (FEV1.0 more than 500 ml/DSA, performance status) must be considered in making the decision to operation. The 5-year survival rate was 67%, 41%, and 33% in cases treated by operation for bilateral lesions, ipsilateral operation and contralateral combination therapy, and non-surgical therapy. Multidisciplinary treatment based on surgical resection contributed to good prognosis of bilateral multiple lung cancers. A long-term detailed follow-up is necessary to detect second lung carcinoma after the first operation as soon as possible.     

异时第二原发肺癌的诊断及手术治疗

目的 探讨异时第二原发肺癌的诊断、手术治疗方式和预后。方法 对我院胸外科自1983年1月至2004年4月手术治疗的32例异时第二原发肺癌患者的临床资料进行回顾性分析。结果 15例有咳嗽、痰血、气短等症状,17例随诊中经影像学检查发现。第一原发肺癌均行肺叶切除或全肺切除。异时第二原发肺癌行肺叶切除或完成式全肺切除17例,局部切除14例,单纯探查1例;15例行淋巴结清扫,17例未清扫淋巴结;6例为姑息性切除。手术切除率和根治切除率分别为97％(31／32)和81％(26／32)。两次手术为同侧者17例(9例为右侧)。组织学类型：鳞癌11例,腺癌7例,腺鳞癌6例,肺泡细胞癌5例,小细胞肺癌、小细胞并鳞癌及腺样囊性癌各1例;第一、二原发肺癌组织学类型不同者24例,组织学类型相同但发现的时间间隔超过4年者7例。术后临床病理分期：Ⅰa期4例,Ⅰb期16例,Ⅱa期1例,Ⅱb期4例,Ⅲa期1例,Ⅲb期5例,左肺上下叶各有一Ⅰa期癌灶者1例。术后并发症发生率、手术死亡率分别为12％(4／32),3％(1／32),并发症为支气管胸膜瘘、心房纤颤和呼吸功能不全,死亡原因为呼吸衰竭;术后1,3,5年生存率分别为660k,(19／29),32％(9／28),19％(4／21)。结论 加强术后随诊和提高鉴别诊断能力是提高第二原发肺癌诊断率的关键。手术切除方式受限和淋巴结清扫不彻底可能是患者预后不佳的原因之一。     

Analyses of multiple primary lung cancers; recent trend]

We studied multiple primary lung cancers (MPLCs) in 921 patients who had undergone operation for primary lung cancer since March 1979 in Mie University Hospital. There were 14 synchronous and 5 metachronous MPLCs. Combination of synchronous MPLCs were adenocarcinoma (ADC)/ADC in 7, squamous cell carcinoma (SCC)/SCC in 3, and ADC/adenosquamous cell carcinoma, ADC/small cell carcinoma, ADC/large cell carcinoma and multiple AAH in one. The incidence of synchronous MPLCs was 0.7% (6/815 pts) before May 1999 and 7.5% (8/106 pts) after June 1999 when HRCT was introduced for preoperative evaluation and postoperative follow-up. Six cases with multiple bronchioloalveolar carcinomas (BACs) have undergone operation for last 5 years. Most of them were roentgenographically occult and the operative outcome was good in spite of limited resection. In summary, we need new strategy of diagnosis and operative procedure for peripheral small adenocarcinoma, because multiple MPLCs of BAC are not rare.     

Bilateral cancer of the breast: a review of clinical, histologic, and immunohistologic characteristics.

The clinical, histologic, and immunohistologic characteristics of 19 synchronous and 47 metachronous bilateral breast cancers was compared. Patients with metachronous tumors were 5 years younger and more likely to have a family history of breast cancer than those patients with synchronous cancers. The nondominant synchronous cancer was usually discovered mammographically accounting for small, node-negative tumors, and high prevalence of in situ lesions. The same was true of the second metachronous tumor when discovered mammographically. Patients with metachronous cancers who were not in a follow-up program had second cancers with characteristics similar to incidentally diagnosed unilateral cancer. The mean interval between metachronous cancers was 101 months. Significantly more first metachronous tumors were invasive lobular cancers. Histologic type of the first and second tumor was the same in only 68% of synchronous and 61% of metachronous cancers. Combined histologic evidence and differentiation was concordant in only 13% and 22% of tumors, respectively. Immunoperoxidase studies were performed with two human milk fat globule antibodies. Each antibody reacted similarly in the first and second tumor in less than 50% of tumors and concordance was less than 25% when both antibody reactions were assessed. Differences in histologic evidence, differentiation, and immunohistologic reaction suggest that both synchronous and metachronous cancers are morphologically and functionally dissimilar.     

Renal tumors and second primary pancreatic tumors: a relationship with clinical impact?

ABSTRACT: BACKGROUND: The occurrence of synchronous or metachronous renal cell carcinoma and pancreatic tumors has been described only in a few cases in the scientific literature. The study of double primary cancers is important because it might provide understanding of a shared genetic basis of different solid tumors and to detect patients at risk for secondary malignancy. METHODS: In a combined analysis of patient registries from University Departments of Urology and Visceral Surgery, 1178 patients with pancreatic tumors and 518 patients with renal cell carcinoma treated between 2001 and 2008 were evaluated, RESULTS: Overall 16 patients with renal cancer and synchronous (n = 6) or metachronous (n = 10) primary pancreatic tumors were detected. The median survival of all patients was 12.6 months, for the patients with synchronous resections 25.7 months and for the patients with metachronous resections 12.2 months, respectively. CONCLUSIONS: The association between these two etiologies of malignancy demands more detailed epidemiological and molecular investigation. Clinical outcomes would support a resection as a recommended clinically valid option.     

A case report of double roentgenographically occult lung cancer revealed by postsurgical pathological study]

A 66-year-old man admitted to our hospital as a roentgenographically occult lung cancer (ROLC) detected by sputum cytology of class IV. A differential brushing of all branches of the bronchi was performed and squamous cell carcinoma was detected only from the right B8 segmental bronchus. Right lower lobectomy was performed and the microscopic findings of surgical specimen revealed the squamous cell carcinomas were seen at not only B8 bronchus but also B7 bronchus. The frequency of multicentricity of ROLC is reported to be high, and a differential bronchial brushing of all bronchi is a very powerful method to diagnose synchronous multiple lung cancer. However, we failed to detect a cancer lesion of B7 segmental bronchus in this case. Since, the outcomes of surgical treatments for either synchronous or metachronous multiple primary lung cancer are satisfactory, limited surgical treatments might be appropriate as an initial treatment for a ROLC.     

Surgical results for multiple primary lung cancers.

OBJECTIVE: The development of a multiple primary lung cancer (MPLC) is not rare in long-term survivors after curative resections. We analysed our experience in order to verify surgical results and long-term survival in our patients. METHODS: From 1971 to 1999, 80 patients with MPLC (two tumours each, total 160) were treated at the Division of Thoracic Surgery of the University of Padua. Our criteria for the definition of a synchronous or metachronous cancer are those proposed by Martini and Melamed. We had 19 patients with a synchronous tumour and 61 patients with a metachronous tumour. We performed 95 lobectomies, 5 completion pneumonectomies and 53 segmentectomies. Of 160 MPLCs, 60 were squamous carcinomas, 78 adenocarcinomas, 8 small cell lung cancers, 9 large cell lung cancers and 5 other tumours. Of 160 MPLCs, 140 were N0 disease (87.5%) and 20 were N1 or N2 disease (12.5%). RESULTS: The overall 30-day mortality was 2.5% (2 patients). Eighteen patients (22.5%) had postoperative complications. Survival at 5 and 10 years for all patients was 72% and 58%, respectively. Five-year survival for patients with metachronous and synchronous disease from the time of initial diagnosis of cancer was 85% and 20% (P=0.001), and 10-year survival was 58% and 0% (P=0.001), respectively. Survival after the development of a metachronous lesion was 51% at 5 years and 20% at 10 years. The 5-year survival of patients with metachronous tumours undergoing standard surgical procedures of the second tumour was 52%; the 5-year survival of patients undergoing atypical or segmental resections was 55%. CONCLUSIONS: Careful follow-up is recommended in all patients surviving curative resection. More accurate selection criteria for MPLC is required. An aggressive surgical approach is justified in patients with MPLC and offers the greatest chance for long-term survival even in the case of limited resection.